Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).

NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).

Related Videos
Ursula Linne-McLaren, RN, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Related Content